ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma.  Final results of the IIL HD9601 randomized trial
Association between androgen deprivation therapy and fracture risk:  A population-based cohort study in men with non-metastatic prostate cancer.
Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? (EORTC 22911)
Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): a prospective, multi-institutional trial
MRI detection of multi focal breast carcinoma:  Report from the International Breast MRI Consortium
Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer
Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)
The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer
What we learned on June 5, 2004
English
News
No new evidence found to support reversal of USPSTF 2004 recommendation against screening

Sep 22, 2010 - No new evidence has emerged warranting a change in the U.S. Preventive Services Task Force's 2004 conclusion that screening asymptomatic men for testicular cancer is unlikely to offer benefits over clinical detection, according to a literature review in the Sept. 21 issue of the Annals of Internal Medicine.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información